Environmental

ZVRA’s R&D intensity is moderate for a biotech peer set, supporting a focused development footprint while avoiding the heavier manufacturing emissions seen in larger pharma peers.

The company’s asset-light profile likely limits direct Scope 1 and 2 exposure versus integrated drugmakers, reducing environmental compliance burden and facility-related transition risk.

Low leverage and negative net debt reduce pressure to prioritize capital-intensive physical expansion, which can help keep environmental liabilities and remediation exposure contained.

Because environmental impact in biotech is driven more by laboratory operations and supply chains than by scale, ZVRA appears broadly aligned with smaller-cap peers rather than advantaged versus best-in-class leaders.

Social

ZVRA’s high gross margin and focused R&D model suggest a concentrated workforce and clinical footprint, which typically lowers broad labor and community exposure versus diversified healthcare peers.

Stock-based compensation remains meaningful relative to revenue, indicating reliance on equity incentives that can support talent retention but also create dilution-related employee alignment scrutiny.

As a development-stage biotech, patient safety and trial conduct are the key social risks, and ZVRA’s smaller operating scale generally reduces the breadth of exposure versus commercial-stage peers.

The company’s social profile appears stronger than many peers because its limited manufacturing and distribution presence reduces product-access, labor, and supply-chain social complexity.

Governance

Very low debt-to-equity suggests conservative capital structure governance, reducing creditor pressure and lowering the likelihood of covenant-driven decision making versus leveraged peers.

Negative net debt indicates liquidity strength, which can improve governance flexibility by reducing refinancing risk and allowing management to focus on long-term clinical execution.

Stock-based compensation near 9.6% of revenue is material, so governance quality depends on disciplined equity issuance and clear alignment between incentives and shareholder dilution.

Overall governance appears solid relative to small-cap biotech peers, though it is not top-tier because compensation intensity and development-stage oversight remain structurally important.

Overall Score

ZVRA screens as a strong relative ESG name versus biotech peers, with its most favorable positioning coming from a low-risk capital structure and limited operational footprint.

Score Driver: Conservative Balance-Sheet Governance And An Asset-Light Operating Model